Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells - Wikidata - awgldk - TriplyDB

Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells

Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells

http://www.wikidata.org/entity/Q30541218

about

Phytochemical modulators of mitochondria: the search for chemopreventive agents and supportive therapeutics Targeting hypoxic response for cancer therapy Harnessing the apoptotic programs in cancer stem-like cells Components of cancer metabolism and therapeutic interventions Regulation of ovarian cancer stem cells or tumor-initiating cells Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-related protein 1.Apoptotic death of cancer stem cells for cancer therapy.ABC transporters in CSCs membranes as a novel target for treating tumor relapse.Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.Ovulation and extra-ovarian origin of ovarian cancer Stem cell pathways contribute to clinical chemoresistance in ovarian cancer Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors Ovarian cancer stem cells: are they real and why are they important?Mitochondria as therapeutic targets for cancer stem cells.Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines TRA-1-60(+), SSEA-4(+), Oct4A(+), Nanog(+) Clones of Pluripotent Stem Cells in the Embryonal Carcinomas of the Ovaries TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential Aiming to immune elimination of ovarian cancer stem cells Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1)Novel pharmacological modulators of autophagy and therapeutic prospects.Investigating molecular profiles of ovarian cancer: an update on cancer stem cells.Therapeutic potential of mTOR inhibitors for targeting cancer stem cells.Emerging importance of dietary phytochemicals in fight against cancer: Role in targeting cancer stem cells.Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344.Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells Parkin and mitophagy in cancer.Anti-cancer analogues ME-143 and ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I).A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia Licochalcone A specifically induces cell death in glioma stem cells via mitochondrial dysfunction.microRNA-488 inhibits chemoresistance of ovarian cancer cells by targeting Six1 and mitochondrial function.Peroxiredoxin 3 maintains the survival of endometrial cancer stem cells by regulating oxidative stress.Adipocyte microenvironment promotes Bclxl expression and confers chemoresistance in ovarian cancer cells.Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo.Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance.

P2860

Q24562914-5D3F3CEE-A6A4-4A51-AD42-4E50C05887F2 Q26767351-861A1E7D-51DD-4A4A-8115-96291BB6F4E8 Q26801037-3672A755-930A-4C3D-9F7E-A35E3B898993 Q26823746-9509C03E-CAAE-493A-BB6F-B45B54F5A105 Q26853096-8BA50085-68EB-453D-B7CE-0E9AA8695DEB Q30409503-FAA3909D-28EF-4CBF-812D-87ACEFD3EC6E Q33440037-EC0E0B15-5375-48E4-9742-A20E3616E5FC Q33588277-14B394A8-EE69-4091-ABFA-B11907006957 Q33755766-6DFF2B41-7AD0-4F8F-928E-10B3B02D1575 Q33879326-29569B2D-5ECE-423B-8DFC-060535055E5C Q33914038-6FAA2E88-CACF-41FF-8FFF-841F97176597 Q34063581-1354571D-5EE5-4FAB-B93F-EE38FD938C07 Q34092005-170E8259-7DB7-4844-8D00-B314C7B0AC97 Q34483738-3D765E71-F77E-46BE-933B-545A757B7C2B Q35047699-D71AE37E-0012-411D-8584-792E0A89B5B7 Q35205681-448642FB-D63F-4268-AB91-C337990896DE Q35522903-22ACC9A2-8F18-4218-B7F5-96D1FEF7EA1D Q35649272-109BDE73-4B80-4CDD-986C-F48CDCA447A7 Q36503165-5356E205-5054-4B44-9FF4-7D37B2190A51 Q36654413-8FE825EE-5806-4065-8F25-AAE841903884 Q36989636-2EE4FDF7-A02D-49C5-9256-AF6ECDAE3175 Q37266548-8EB9ECF3-4578-46D9-BE9A-EEA6F1C51899 Q37481128-22A3FD80-FBBE-42EF-873F-2D7E1EF82776 Q37639235-013204B0-E3CA-44EE-92D1-586743116F67 Q38031895-A728C66B-995E-427F-8B88-5585C9F9FAF9 Q38203882-E966C337-78D0-48EE-B22A-0ECB9AF8B6F6 Q38648562-0AE897E7-923C-450C-A1E4-5565D3094872 Q38725554-582FA197-2DFF-4A61-9449-B0A22518844D Q38766970-5ED844BA-5EB0-4BD2-818D-563F165138FF Q38813996-24DF55EC-1725-4207-B834-B185EDD94404 Q38862527-28F4EE17-478B-4456-B014-62331C48956E Q38946190-5AB99F87-D438-4FCB-A6BB-62D287778966 Q39006957-F454C3DC-4214-4852-906E-65D37B24C5C7 Q41266779-67B3173F-3568-420B-882F-26038B82FFD0 Q42222793-D8138D86-C0E6-4FDD-9E51-72B9E6D66369 Q43279631-B80E5BB3-FD80-4DCE-ABB5-94A2E91854D6 Q46250941-E865AA66-F92E-4A52-A156-18A2F01128B3 Q51238643-3BF5D000-6CE2-4F8A-9D8D-7B3817C95961 Q52639388-3C6F28CA-0AEA-47EC-B246-627948921B35 Q53697399-9DFF15B1-0A3B-4B16-9D31-90CE695ADE1F

P2860

Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells

http://www.wikidata.org/entity/Q30541218

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Targeting the mitochondria act ...... s in ovarian cancer stem cells

@ast

Targeting the mitochondria act ...... s in ovarian cancer stem cells

@en

type

label

Targeting the mitochondria act ...... s in ovarian cancer stem cells

@ast

Targeting the mitochondria act ...... s in ovarian cancer stem cells

@en

prefLabel

Targeting the mitochondria act ...... s in ovarian cancer stem cells

@ast

Targeting the mitochondria act ...... s in ovarian cancer stem cells

@en

P1433

Q30541218-3FDED9C6-BE3E-4950-8F7C-696914C89A78

P1476

Q30541218-054A888D-3FFA-4B99-B647-28F7D492A9E6

P2093

Q30541218-320EE4D0-36F4-4FA9-80C7-45CF48956016

Q30541218-CDAEA58B-FB86-432F-8D52-D7892A5DEDA4

Q30541218-DAA78AC4-E64A-485E-BC50-5EE624FF3644

Q30541218-E5F20489-A52F-4709-95FC-F3BF87E84458

Q30541218-F68CE22F-1E58-49FF-BDF3-44783E63D3C6

Q30541218-F9177334-5A31-4F64-B696-7FE98A10E970

P2860

Q30541218-1245895C-617E-45B4-B955-265DDA0FBF05

Q30541218-142BB7E4-462E-4770-A796-ECF6B4AC78B2

Q30541218-1AC2C4D2-7119-4DBA-836F-B29AF1798EF8

Q30541218-3405C951-3D18-4F64-80B6-A6F29C6FDFBE

Q30541218-35097EF1-40A6-4F38-8524-ABBE8619A6B1

Q30541218-4E18D200-1C05-402E-9AB7-20201694A200

Q30541218-5CAC56C5-FA8A-4350-A5A3-2A4E98926B79

Q30541218-5EE1B5E8-809C-41C4-B68D-C1EE697D0FB7

Q30541218-61CE8D80-0BEE-47EA-8C35-79AF419A99DF

Q30541218-63FC0759-FF5B-4178-BA6A-E1291A0F6BC6

P304

Q30541218-7073B5FE-927E-4AF1-8C3D-ECA2B4F3AF76

P31

Q30541218-B133F8E3-787F-4E3D-A466-1CE79FF51FDE

P356

Q30541218-50424B5A-0C54-4B74-B445-7F19073A5F66

P433

Q30541218-EF3F2416-8983-45A3-B611-165CA692ADB3

P478

Q30541218-0941E4CA-6E06-405F-9307-8ED5998EEF96

P577

Q30541218-E2B3A9F0-F202-4CD7-B75D-AF5728F797B2

P698

Q30541218-37C3B557-A9B2-43D3-89FC-BE39D79F37FA

P921

Q30541218-0522FE37-4F4C-43D1-A7EB-17A0A4C8C521

Q30541218-567203AC-B778-457B-BD36-278C91EA221C

P932

Q30541218-8D46FB34-A006-4367-A4F7-903F51C21418

P356

1535-7163.MCT-11-0023

P1433

Molecular Cancer Therapeutics

P1476

Targeting the mitochondria act ...... s in ovarian cancer stem cells

@en

P2093

Ayesha B Alvero

http://www.w3.org/2001/XMLSchema#string

David Brown

http://www.w3.org/2001/XMLSchema#string

Gil Mor

http://www.w3.org/2001/XMLSchema#string

Jennie C Holmberg

http://www.w3.org/2001/XMLSchema#string

Michele K Montagna

http://www.w3.org/2001/XMLSchema#string

Vinicius Craveiro

http://www.w3.org/2001/XMLSchema#string

P2860

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

Chemoresistance in human ovarian cancer: the role of apoptotic regulators

TSC2 mediates cellular energy response to control cell growth and survival

Current development of mTOR inhibitors as anticancer agents

Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells

The MAPK signaling cascade

Cancer cell metabolism: Warburg and beyond

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

Cancer statistics, 2009

The Bcl2 family: regulators of the cellular life-or-death switch

P304

1385-1393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-11-0023

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21677151

http://www.w3.org/2001/XMLSchema#string

P921

P932

3703662

http://www.w3.org/2001/XMLSchema#string